Intersect ENT Obtains Reimbursement Designation for Propel Sinus Implant in Germany

InEk, the German Institute for the Hospital Remuneration System, has assigned NUB Status 1 for reimbursement of Intersect ENT’s mometasone furoate implants for 2016, the company announced.

The purpose of the NUB process is to support the introduction of innovative medical products by allowing a limited number of participating hospitals to receive reimbursement.

NUB Status 1 is the highest priority designation available, and was only assigned to a minority of product submissions for 2016, Intersect ENT says. — Jonathon Shacat